Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489013 | 0.92 | PLK1 (0.52) | PLK1PLK3PRMT5WDR77 | |
| SCHEMBL2532211 | 0.88 | KDM4E (0.49) | KDM4ETSHR | |
| SCHEMBL2536136 | 0.88 | AVPR1B (0.49) | KDM4ETSHR | |
| SCHEMBL2532294 | 0.87 | AVPR1B (0.47) | SMN1; SMN2KDM4ETSHR | |
| SCHEMBL2490863 | 0.84 | JAK2 (0.46) | PLK1PLK3L3MBTL1SMN1; SMN2MAPK1 | |
| SCHEMBL2491218 | 0.81 | PLK1 (0.44) | PLK1PLK3 | |
| SCHEMBL2538071 | 0.81 | PLK1 (0.43) | PLK1PLK3 | |
| SCHEMBL2488199 | 0.81 | HRH3 (0.44) | PLK1PLK3KDM4EPOLB | |
| SCHEMBL2540425 | 0.81 | AVPR1B (0.47) | PLK1PLK3 | |
| SCHEMBL2539260 | 0.81 | PLK1 (0.42) | PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | claimed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | claimed |
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | PLK1 2782/4885PLK3 1584/4885L3MBTL1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.